Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of AVB-S6-500 in Patients With Clear Cell Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04300140
Recruitment Status : Not yet recruiting
First Posted : March 9, 2020
Last Update Posted : March 9, 2020
Sponsor:
Information provided by (Responsible Party):
Aravive, Inc.

Brief Summary:
This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment. The phase 1b portion of the study is open label and patients will receive AVB-S6-500+Cabozantinib in 3+3 dose escalation. The Phase 2 portion of the study is randomized, open-label study to compare efficacy and tolerability of AVB-S6-500+cabozantinib versus cabozantinib alone

Condition or disease Intervention/treatment Phase
Clear Cell Renal Cell Carcinoma Drug: AVB-S6-500 Drug: Cabozantinib (Cabo) Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2, Randomized, Study of AVB-S6-500 in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Advanced Clear Cell Renal Cell Carcinoma That Have Received Front-Line Treatment
Estimated Study Start Date : March 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : March 2023


Arm Intervention/treatment
Experimental: Phase 1b: AVB-S6-500+Cabo Drug: AVB-S6-500
AVB-S6-500 is experimental drug

Drug: Cabozantinib (Cabo)
Cabo is active comparator
Other Name: Cabometyx®

Experimental: Phase 2: AVB-S6-500+Cabo Drug: AVB-S6-500
AVB-S6-500 is experimental drug

Drug: Cabozantinib (Cabo)
Cabo is active comparator
Other Name: Cabometyx®

Experimental: Phase 2: Cabo alone Drug: Cabozantinib (Cabo)
Cabo is active comparator
Other Name: Cabometyx®




Primary Outcome Measures :
  1. Incidence of Adverse Events (AEs) [ Time Frame: 9 months ]
    Measured by the number of patients with AEs in Phase 1 portion of the study.

  2. Anti-tumor activity of AVB-S6-500 in combination with Cabozantinib [ Time Frame: 30 months ]
    Measured by progression free survival (PFS) in patients receiving AVB-S6-500+Cabo versus patients receiving Cabo alone in Phase 2 portion of the study.


Secondary Outcome Measures :
  1. Pharmacokinetics: AUC [ Time Frame: 30 months ]
    Area under the AVB-S6-500 concentration-time curve.

  2. Pharmacokinetics: Cmax [ Time Frame: 30 months ]
    Maximum observed AVB-S6-500 concentration.

  3. Pharmacokinetics: Tmax [ Time Frame: 30 months ]
    Time of maximum observed AVB-S6-500 concentration.

  4. Pharmacokinetics: t1/2 [ Time Frame: 30 months ]
    Apparent terminal half-life of AVB-S6-500.

  5. Pharmacodynamic marker assessment [ Time Frame: 30 months ]
    Change from the baseline in GAS6 serum levels.

  6. Anti-drug antibody (ADA) titers [ Time Frame: 30 months ]
    Change from baseline in ADA titer.

  7. Objective response rate [ Time Frame: 30 months ]
    Proportion of subjects who have a partial or complete response to therapy relative to baseline as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

  8. Disease control rate [ Time Frame: 30 months ]
    Proportion of subjects who have a complete or partial response to therapy or maintain stable disease.

  9. Duration of response (DOR) [ Time Frame: 30 months ]
    Measured from the date of partial or complete response to therapy until the cancer progresses.

  10. Overall survival [ Time Frame: 60 months ]
    Time following the treatment until death.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Histologically confirmed stage IV clear cell Renal Cell Carcinoma and has progressed on/after or was intolerant to front-line treatment
  • Must have radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within 4 weeks of enrollment
  • Must have at least one measurable lesion according to RECIST 1.1
  • ECOG performance status of 0-1
  • Adequate gastrointestinal (GI), bone marrow, liver and kidney function
  • Life expectancy minimum of 12 weeks
  • At least 14 days between termination of prior anticancer and administration of AVB-S6-500

Exclusion Criteria:

  • Received prior treatment with cabozantinib
  • Currently being treated with concurrent anti-cancer therapy or any other interventional treatment or trial
  • Significant cardiac disease history
  • Has other prior or concurrent malignancy within the past 3 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast
  • Symptomatic CNS metastasis or metastases
  • Active GI disease that would impact absorption of cabozantinib
  • Nephrotic range proteinuria at screening
  • Has had a major bleed in the last 3 months, uncontrolled hypertension despite treatment with Antihypertensives or is not appropriate for treatment with cabozantinib in the Investigator's opinion
  • Serious active infection requiring IV antibiotics and/or hospitalization at study entry
  • Has active, suspected, or previously documented autoimmune disease, defined as requiring systemic treatment
  • Has known human immune deficiency (HIV) syndrome, hepatitis B, or hepatitis C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04300140


Contacts
Layout table for location contacts
Contact: Aravive Clinical Trials 281-810-6749 clinicaltrials@aravive.com

Locations
Layout table for location information
United States, Nevada
Nevada Cancer Care Network
Las Vegas, Nevada, United States, 89169
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10024
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Tennessee
Vanderbilt-Ingram Cancer Center (VICC)
Nashville, Tennessee, United States, 37232
Contact: VICC Clinical Trials Reporting Program    800-811-8480      
Sponsors and Collaborators
Aravive, Inc.
Investigators
Layout table for investigator information
Study Director: Laura Bonifacio, PharmD, PhD Aravive, Inc.
Layout table for additonal information
Responsible Party: Aravive, Inc.
ClinicalTrials.gov Identifier: NCT04300140    
Other Study ID Numbers: AVB500-RCC-003
First Posted: March 9, 2020    Key Record Dates
Last Update Posted: March 9, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aravive, Inc.:
Clear cell renal cell carcinoma
Renal cell carcinoma
Kidney cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases